Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | WNT1 | P04628 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | MAP3K5 | Q99683 | 7/20 | 0.40 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.40 |
| ▸ | TMPRSS2 | O15393 | 4/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
| ▸ | CLK3 | P49761 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20364362 | 0.94 | ESR2 (0.55) | ESR2HDAC6HDAC8NR1H2WNT1 | |
| SCHEMBL20162154 | 0.87 | MAP3K5 (0.37) | ESR2NR1H2MAP3K5 | |
| SCHEMBL20364364 | 0.82 | ESR2 (0.53) | ESR2HDAC6HDAC8NR1H2WNT1 | |
| SCHEMBL20364366 | 0.81 | MAPT (0.41) | ESR2NR1H2MAP3K5 | |
| SCHEMBL20364363 | 0.81 | ESR2 (0.48) | ESR2HDAC6HDAC8NR1H2MAP3K5 | |
| SCHEMBL20364361 | 0.77 | ESR2 (0.55) | ESR2HDAC6HDAC8NR1H2WNT1 | |
| SCHEMBL20364337 | 0.77 | ESR2 (0.46) | ESR2HDAC6HDAC8NR1H2WNT1 | |
| SCHEMBL20169969 | 0.77 | ESR2 (0.46) | ESR2HDAC6HDAC8NR1H2WNT1 | |
| SCHEMBL20364347 | 0.76 | TAS2R8 (0.49) | ESR2HDAC6HDAC8NR1H2MAP3K5 | |
| SCHEMBL20170243 | 0.76 | ESR2 (0.47) | ESR2NR1H2MAP3K5TAS2R8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | NR0B1, NR2E1, NR0B2 | ESR2 620/4885HDAC6 188/4885HDAC8 236/4885 |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | NR0B1, NR2E1, NR0B2 | ESR2 620/4885HDAC6 188/4885HDAC8 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.